Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 2:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 18,611 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Phase 1 Clear all
Completed Phase 1Phase 2 Interventional

Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer

NCT01355393
View directory record Official record
Conditions
HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
HER-2/neu peptide vaccine, sargramostim, rintatolimod
Biological · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Oct 29, 2026, 2:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Four-Way Crossover Study to Compare Ferric Maltol Capsules and Oral Suspension in Healthy Volunteers

NCT04626414
View directory record Official record
Conditions
Anemia, Iron Deficiency
Interventions
Ferric maltol capsule, Ferric maltol suspension
Drug
Lead sponsor
Shield Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 24, 2025 · Synced Oct 29, 2026, 2:27 AM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma

NCT00589784
View directory record Official record
Conditions
CNS Cancer, Meningioma, Intracranial Hemangiopericytoma, Hemangioblastoma, Neurofibromatosis
Interventions
Sunitinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
6
States / cities
Boston, Massachusetts • Basking Ridge, New Jersey • Commack, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2016 · Synced Oct 29, 2026, 2:27 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase I/II Trial of Stereotactic Body Radiation Therapy

NCT00591838
View directory record Official record
Conditions
Inoperable Stage I/II Non-small Cell Lung Cancer
Interventions
Stereotactic Body Radiation Therapy (SBRT)
Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Oct 29, 2026, 2:27 AM EDT
Terminated Phase 1 Interventional

177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic, Castration Resistant Prostate Cancer

NCT03490838
View directory record Official record
Conditions
Prostatic Neoplasm
Interventions
177Lu-PSMA-R2
Drug
Lead sponsor
Advanced Accelerator Applications
Industry
Eligibility
18 Years and older · Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
9
States / cities
Phoenix, Arizona • San Francisco, California • Stanford, California + 6 more
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 29, 2026, 2:27 AM EDT
Completed Phase 3 Interventional

Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension

NCT01508026
View directory record Official record
Conditions
Stage 1 Hypertension, Stage 2 Hypertension
Interventions
Nebivolol and Valsartan 1, Nebivolol and Valsartan 2, Nebivolol and Valsartan 3, Nebivolol 1, Nebivolol 2, Valsartan 1, Valsartan 2, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
4,161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
413
States / cities
Birmingham, Alabama • Foley, Alabama • Gulf Shores, Alabama + 290 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2014 · Synced Oct 29, 2026, 2:27 AM EDT
Terminated Phase 1 Interventional Results available

A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)

NCT02616185
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
PF-06755992, PF-06755990, TDS-IM Electroporation Device, Tremelimumab, PF-06801591, PF-06753512
Biological · Device
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
19
States / cities
Tucson, Arizona • New Haven, Connecticut • Bethesda, Maryland + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Oct 29, 2026, 2:27 AM EDT
Completed Phase 2 Interventional Results available

Choroideremia Gene Therapy Clinical Trial

NCT02553135
View directory record Official record
Conditions
Choroideremia
Interventions
Injection of AAV2-REP1 (10e11 vg)
Biological
Lead sponsor
Byron Lam
Other
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Oct 29, 2026, 2:27 AM EDT
Completed Phase 1 Interventional

Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function (POM Renal)

NCT01575925
View directory record Official record
Conditions
Multiple Myeloma, Renal Impairment
Interventions
4 mg Oral POM + 40 mg Oral DEX, 2 mg Oral POM + 40 mg Oral DEX
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
7
States / cities
Denver, Colorado • Atlanta, Georgia • Harvey, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2022 · Synced Oct 29, 2026, 2:27 AM EDT
Recruiting Phase 1Phase 2 Interventional

PDS01ADC Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma

NCT04303117
View directory record Official record
Conditions
Kaposi Sarcoma
Interventions
PDS01ADC, M7824
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 29, 2026, 2:27 AM EDT
Terminated Phase 1Phase 2 Interventional

Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer

NCT01471964
View directory record Official record
Conditions
Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Recurrent
Interventions
MLN8237 and Erlotinib
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Oct 29, 2026, 2:27 AM EDT
Completed Phase 2 Interventional Results available

Donor Stem Cell Transplant in Treating Patients With Previously Treated Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

NCT00612716
View directory record Official record
Conditions
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Interventions
busulfan, cyclophosphamide, Stem cell infusion, Total body irradiation
Drug · Biological · Radiation
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 55 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Oct 29, 2026, 2:27 AM EDT
Terminated Phase 1 Interventional

A Study of DSP-0337 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile

NCT03416816
View directory record Official record
Conditions
Neoplasms
Interventions
DSP-0337
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
Indianapolis, Indiana • Detroit, Michigan • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Oct 29, 2026, 2:27 AM EDT
Recruiting Phase 1 Interventional

A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia

NCT07011004
View directory record Official record
Conditions
Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse
Interventions
Cytokine Induced Memory-Like Natural Killer Cells, Atezolizumb, CIML-NK cell therapy
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 29, 2026, 2:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Study of Group B Meningococcal Vaccine to Prevent Meningitis.

NCT00248833
View directory record Official record
Conditions
Meningitis, Meningococcal, Serogroup B
Interventions
25ug Group B Meningococcal 44/76 MOS NOMV 5D Vaccine, 50ug Group B Meningococcal 44/76 MOS NOMV 5D Vaccine
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 45 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 29, 2018 · Synced Oct 29, 2026, 2:27 AM EDT
Recruiting Phase 1 Interventional

TLI, TBI, ATG & Hematopoietic Stem Cell Transplantation and Recipient T Regs Therapy in Living Donor Kidney Transplantation

NCT03943238
View directory record Official record
Conditions
Living Donor Kidney Transplantation
Interventions
Infusion of Donor Hematopoetic Stem Cells and Recipient Tregs
Biological
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
2
States / cities
Palo Alto, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 29, 2026, 2:27 AM EDT
Completed Phase 1 Interventional

Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

NCT02337426
View directory record Official record
Conditions
Adult Brain Glioblastoma, Adult Giant Cell Glioblastoma, Adult Gliosarcoma
Interventions
Dimethyl Fumarate, Temozolomide, Radiation Therapy
Drug · Radiation
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 28, 2019 · Synced Oct 29, 2026, 2:27 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer

NCT03106415
View directory record Official record
Conditions
Breast Adenocarcinoma, Metastatic Triple-Negative Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Binimetinib, Laboratory Biomarker Analysis, Pembrolizumab
Drug · Other · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 27, 2025 · Synced Oct 29, 2026, 2:27 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

QUILT-3.010: A Study of Gemcitabine and Nab-paclitaxel With or Without NPC-1C to Treat Patients With Pancreatic Cancer

NCT01834235
View directory record Official record
Conditions
Pancreatic Cancer, Adult
Interventions
Gemcitabine, nab-paclitaxel, NPC-1C
Drug
Lead sponsor
Precision Biologics, Inc
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
12
States / cities
San Francisco, California • New Haven, Connecticut • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 7, 2025 · Synced Oct 29, 2026, 2:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Safety, Tolerability, and PK of EDG-5506 in Healthy Volunteers and Becker Muscular Dystrophy Adults

NCT04585464
View directory record Official record
Conditions
Healthy Volunteer, Becker Muscular Dystrophy
Interventions
EDG-5506, Placebo
Drug
Lead sponsor
Edgewise Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Oct 29, 2026, 2:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of TAK-951 in Healthy Adults

NCT05567393
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-951 Placebo, TAK-951
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced Oct 29, 2026, 2:27 AM EDT
Recruiting Early Phase 1 Interventional

A Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies.

NCT07017816
View directory record Official record
Conditions
CNS Malignancies, Medulloblastoma Recurrent, ATRT Recurrent, Pineoblastoma, Embryonal Neoplasm, Ependymoma Recurrent, High Grade Gliomas
Interventions
SGT-53, hypofractionated radiotherapy with immunotherapy, Nivolumab
Drug · Radiation
Lead sponsor
Children's National Research Institute
Other
Eligibility
3 Years to 21 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 29, 2026, 2:27 AM EDT
Terminated Phase 1 Interventional

A Phase 1 Study Of An Intravenously Administered Cyclin-Dependent Kinase Inhibitor In Patients With Advanced Cancer

NCT00147485
View directory record Official record
Conditions
Neoplasms, Lymphoma, Non-Hodgkin
Interventions
AG-024322
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
4
States / cities
Boston, Massachusetts • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 18, 2008 · Synced Oct 29, 2026, 2:27 AM EDT
Active, not recruiting Phase 1 Interventional

Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors

NCT02608385
View directory record Official record
Conditions
Solid Tumor
Interventions
Stereotactic body radiotherapy (SBRT), Pembrolizumab
Radiation · Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 8, 2025 · Synced Oct 29, 2026, 2:27 AM EDT